☀️     🌓

Prescribing Advice for GPs

An NHS Prescribing Advisers' Blog

Leuprorelin dual chamber syringe

The manufacturer of leuprorelin (Prostap®) injections has written to healthcare professionals advising that the current presentation will be replaced with effect from the 4th of July 2011 and with a dual chamber syringe (DCS) system.

The one month (Prostap SR) and three month (Prostap 3) presentations are both affected by this change with the product license and price remaining unchanged. The manufacturer reports that the DCS system is simple to use and that the existing products will be discontinued in October 2011.

Action: Clinicians should be aware of this product presentation change. Clinicians who use Prostap products should ensure that usage instructions for the new product are followed.

Share 'Leuprorelin dual chamber syringe' by emailShare 'Leuprorelin dual chamber syringe' on FacebookShare 'Leuprorelin dual chamber syringe' on TwitterShare 'Leuprorelin dual chamber syringe' on LinkedInShare 'Leuprorelin dual chamber syringe' on reddit


No Comments to “Leuprorelin dual chamber syringe”

Leave a Comment

Your email address will not be published. Required fields are marked *

Please be aware that you comment is subject to our Privacy Policy.

This site uses Akismet to reduce spam. Learn how your comment data is processed.

Prescribing Advice for GPs is powered by ClassicPress.
Connect to our RSS or Atom Feeds.